R&D Division, Kyowa Kirin Co. Ltd, Tokyo, Japan.
R&D Division, Kyowa Kirin Co. Ltd, Shizuoka, Japan.
Acta Crystallogr D Struct Biol. 2023 May 1;79(Pt 5):435-441. doi: 10.1107/S205979832300311X. Epub 2023 Apr 26.
Structure determination of G-protein-coupled receptors (GPCRs) is key for the successful development of efficient drugs targeting GPCRs. BRIL is a thermostabilized apocytochrome b (with M7W/H102I/R106L mutations) from Escherichia coli and is often used as a GPCR fusion protein for expression and crystallization. SRP2070Fab, an anti-BRIL antibody Fab fragment, has been reported to facilitate and enhance the crystallization of BRIL-fused GPCRs as a crystallization chaperone. This study was conducted to characterize the high-resolution crystal structure of the BRIL-SRP2070Fab complex. The structure of the BRIL-SRP2070Fab complex was determined at 2.1 Å resolution. This high-resolution structure elucidates the binding interaction between BRIL and SRP2070Fab. When binding to BRIL, SRP2070Fab recognizes conformational epitopes, not linear epitopes, on the surface of BRIL helices III and IV, thereby binding perpendicularly to the helices, which indicates stable binding. Additionally, the packing contacts of the BRIL-SRP2070Fab co-crystal are largely due to SRP2070Fab rather than BRIL. The accumulation of SRP2070Fab molecules by stacking is remarkable and is consistent with the finding that stacking of SRP2070Fab is predominant in known crystal structures of BRIL-fused GPCRs complexed with SRP2070Fab. These findings clarified the mechanism of SRP2070Fab as a crystallization chaperone. Moreover, these data will be useful in the structure-based drug design of membrane-protein drug targets.
G 蛋白偶联受体(GPCR)结构的确定是开发针对 GPCR 的高效药物的关键。BRIL 是来自大肠杆菌的热稳定脱细胞细胞色素 b(具有 M7W/H102I/R106L 突变),常用于表达和结晶融合 GPCR 的 GPCR 融合蛋白。SRP2070Fab 是一种抗 BRIL 抗体 Fab 片段,已被报道作为结晶伴侣促进和增强 BRIL 融合 GPCR 的结晶。本研究旨在表征 BRIL-SRP2070Fab 复合物的高分辨率晶体结构。该 BRIL-SRP2070Fab 复合物的结构在 2.1 Å 分辨率下确定。该高分辨率结构阐明了 BRIL 和 SRP2070Fab 之间的结合相互作用。当与 BRIL 结合时,SRP2070Fab 识别 BRIL 螺旋 III 和 IV 表面的构象表位,而不是线性表位,从而垂直于螺旋结合,表明稳定结合。此外,BRIL-SRP2070Fab 共晶的堆积接触主要归因于 SRP2070Fab,而不是 BRIL。SRP2070Fab 分子的堆积堆积量很大,这与已知的与 SRP2070Fab 复合的 BRIL 融合 GPCR 晶体结构中 SRP2070Fab 堆积占主导地位的发现一致。这些发现阐明了 SRP2070Fab 作为结晶伴侣的机制。此外,这些数据将有助于基于结构的膜蛋白药物靶标药物设计。